Cost Modeling for Alternate Routes of Administration of Opioids for Cancer Pain
May 1st 1999The economic considerations relative to neuraxial infusion can be looked at with different types of economic models, including cost-minimization, cost-effectiveness, and cost-benefit analyses. A theoretical predictive model
A 15-Year-Old Boy With Primitive Neurectodermal Tumor
Dr. Peter Staats presented the case of a 15-year-old, 40-kg boy with a primitive neurectodermal tumor located in
Neuraxial Infusion for Pain Control: When, Why, and What to Do After the Implant
May 1st 1999Neuraxial infusion therapy is an excellent option for selected patients with severe pain. Both epidural and intrathecal systems can be effective for multiple pains and are titratable, nondestructive, and very safe.
Managing Cancer Pain Poorly Responsive to Systemic Opioid Therapy
May 1st 1999Large surveys of populations with cancer pain indicate that as many as 90% of patients can attain adequate relief of pain using optimal, systemic, opioid-based pharmacotherapy. Skilled clinicians should be able to achieve
ARF Tumor-Suppressor Gene: A Natural Defense Against Cancer
May 1st 1999Scientists at Cold Spring Harbor Laboratory and St.Jude Children’s Research Hospital in Memphis, Tennessee, provide new information about one of the key “gatekeepers” of cellular health: the p19ARF (ARF) tumor-suppressor gene in an article